Business Context and Reporting Period
MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on small-molecule therapies for serious diseases with unmet medical needs. This Form 10-K covers the fiscal year ended December 31, 2016, including fourth-quarter results. The company had no products approved for commercial sale and no product-sales revenue.
- Primary programs: MN-166 (ibudilast) for progressive multiple sclerosis, ALS and addiction-related indications; and MN-001 (tipelukast) for NASH and idiopathic pulmonary fibrosis.
- Additional programs: MN-221 for acute asthma exacerbations and MN-029 for solid tumors.
- The company had 10 full-time employees and relied substantially on investigators, contract research organizations, third-party manufacturers and potential strategic partners.
Financial Performance and Liquidity
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research, development and patent expense | $3.5 million | $3.0 million | Increased $0.5 million |
| General and administrative expense | $7.4 million | $5.8 million | Increased $1.6 million |
| Total operating expenses | $10.9 million | $8.8 million | Increased $2.1 million |
| Net loss | $10.9 million | $8.8 million | Loss increased $2.0 million |
| Basic and diluted loss per share | $0.33 loss | $0.33 loss | Unchanged |
| Cash used in operating activities | $6.5 million | $7.2 million | Improved $0.6 million |
| Cash and cash equivalents at year-end | $24.1 million | $22.1 million | Increased $2.0 million |
| Working capital at year-end | $23.1 million | $21.2 million | Increased $1.8 million |
Fourth-quarter 2016 operating expenses were $1.4 million and net loss was $1.4 million, or $0.04 per share, compared with fourth-quarter 2015 operating expenses of $2.7 million and net loss of $2.7 million, or $0.09 per share. The filing attributes the annual expense increases primarily to higher performance-based stock compensation and increased legal fees.
Financing activities provided $8.7 million in 2016, including $7.6 million of gross proceeds from warrant exercises and $0.3 million of gross ATM equity proceeds. Total liabilities were $5.3 million at year-end, including $2.0 million of deferred tax liability and $1.7 million of long-term deferred revenue. The filing does not report material interest-bearing debt at year-end.
Material Changes Versus the Prior Comparable Period
- Annual net loss increased from $8.8 million to $10.9 million, while revenue remained zero.
- Research, development and patent expense increased 17%, primarily reflecting higher personnel and program costs.
- General and administrative expense increased 27%, primarily due to performance-based stock compensation and legal fees.
- Noncash share-based compensation increased to $4.0 million from $2.0 million.
- Cash increased despite the operating loss, supported by $8.7 million of financing proceeds.
- Kissei converted 220,000 preferred shares into 2.2 million common shares in June 2016. Year-end common shares outstanding increased to approximately 34.5 million from 30.0 million.
- During 2016, 2.1 million warrants were exercised for $7.6 million of gross proceeds; 1.1 million warrants remained outstanding at year-end.
Clinical Development, Outlook and Risks
- The Phase 2b progressive MS trial of MN-166 completed randomization of 255 subjects. An external data and safety monitoring board recommended continuation after an interim efficacy review; final results were expected in the second half of 2017.
- MN-166 ALS and ALS biomarker studies were ongoing. MN-166 received FDA orphan-drug designation for ALS and European orphan medicinal product designation, in addition to previously granted Fast Track status.
- MN-001 trials in NASH and IPF were ongoing. MN-001 had FDA Fast Track designation for NASH with fibrosis and Fast Track and orphan-drug designations for IPF.
- Further MN-221 development was dependent on obtaining a partner to provide financial support. The Chinese joint venture had not entered into the required sublicense for MN-221 and its ability to proceed was uncertain.
- Management expected research and development expense to increase in 2017 as it focused on MN-166 and MN-001. Management stated that available working capital was expected to fund operations through the end of 2018, but emphasized that additional financing or partnerships may be required.
- The company expected continued operating losses for the foreseeable future and did not expect product-sales revenue for at least several years, if ever.
- Key risks include clinical-trial failure or delay, regulatory non-approval, limited intellectual-property protection for MN-166 and MN-001 active ingredients, dependence on third parties, inability to secure partnerships or financing, dilution from equity issuance, and manufacturing and product-liability risks.
- Potential future license milestone payments totaled $10.0 million for products currently in development and $33.5 million for other products; timing was not estimable. Contractual obligations disclosed totaled $2.5 million, primarily remaining research and development services and leases.
- The company had no material legal proceedings, and management and the independent auditor reported effective disclosure controls and internal control over financial reporting.
Investor Verification Priorities
- Verify subsequent clinical results for the progressive MS and ALS MN-166 programs, including whether interim findings translated into statistically significant final outcomes.
- Assess the company’s cash runway against the stated end-of-2018 estimate, planned 2017 development spending and any subsequent capital raises.
- Review regulatory progress, trial enrollment, safety data and financing requirements for MN-001 in NASH and IPF.
- Confirm outstanding warrants, ATM availability and potential dilution from warrants, stock options and future equity issuance.
- Evaluate the strength and remaining term of patent protection, particularly because composition-of-matter patents for MN-166 and MN-001 had expired.
- Monitor the unresolved MN-221 China sublicense and the company’s dependence on third-party collaborators, manufacturers and potential commercialization partners.